Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States-Reference-Cited by-同舟云学术

Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States

Published:2018-05-07 Issue:3 Volume:39 Page:191-200
ISSN:1088-5412
Container-title:Allergy and Asthma Proceedings
language:en
Short-container-title:allergy asthma proc

Author:

Eghrari-Sabet Jacqueline¹,Sher Ellen²,Kavati Abhishek³,Pilon Dominic⁴,Zhdanava Maryia⁴,Balp Maria-Magdalena⁵,Lefebvre Patrick⁴,Ortiz Benjamin³,Bernstein Jonathan A.⁶

Affiliation:

1. From the Family Allergy and Asthma Care, Gaithersburg, Maryl

2. Atlantic Research Center, LLC, Ocean, New Jersey

3. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

4. Analysis Group, Montréal, Quebec, Canada

5. Novartis Pharma AG, Basel, Switzerl

6. Bernstein Clinical Research Center, Cincinnati, Ohio

Publisher

Oceanside Publications Inc.

Subject

Pulmonary and Respiratory Medicine,General Medicine,Immunology and Allergy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria;World Allergy Organization Journal;2024-01

2. Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria;Clinical and Experimental Dermatology;2022-11-01

3. Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020;Annals of Allergy, Asthma & Immunology;2022-05

4. Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria;International Archives of Allergy and Immunology;2022

5. The Role of Anti-IgE Antibodies in Urticaria;Urticaria - Diagnosis and Management;2021-10-20